• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Synteract to acquire Harrison Clinical Research

Synteract to acquire Harrison Clinical Research

December 20, 2012
CenterWatch Staff

CRO Synteract, a portfolio company of San Francisco-based Gryphon Investors, has agreed to acquire Harrison Clinical Research (HCR).

HCR, founded in 1987, is headquartered in Munich, Germany, with operations in Europe, Israel and South America, in addition to a U.S. office in Princeton, N.J. Synteract plans to combine operations to become a global service provider.

The acquisition of HCR gives Synteract additional resources and scale to support large, global programs, and adds a clinical in-patient unit in Germany and a clinical research training center in Belgium. HCR offers early phase and clinical pharmacology services, phase II-IV capabilities and functional service provision, enabling the combined organization to diversify and deepen its clinical development offerings across therapeutic areas and the spectrum of clinical trials.

A continued directive of the combined company will be to maintain a strong connection with emerging to midsized biopharmaceutical companies, for which both Synteract's and HCR's consultative approach has been central to their relationships with customers.

Wendel Barr, Synteract's CEO, will lead the combined companies. Dr. Francisco Harrison, HCR's chairman and founder, will remain a senior member of the executive team and join the board of directors.  HCR’s existing management will stay in place including CEO Benedikt van Nieuwenhove, who will become head of Europe.

"Harrison Clinical Research is an exceptional fit for Synteract, " said Barr. "Together we will provide a continuum of service that allows us to work with clients throughout their entire development life cycle, from emerging products through post-marketing."

Dr. Harrison stated, "We see this as a growth opportunity that allows us to continue providing our customers with the same personalized service they have come to expect, but on a larger geographic scale. Our shared company cultures and flexible, customizable approaches to managing clinical trials make this a natural fit for us and ensure our clients will continue receiving the same expertise and excellent customer service worldwide." 

With the addition of HCR staff, Synteract will employ over 800 in 16 countries. The transaction is expected to close early in the first quarter of 2013.

Synteract is a portfolio company of Gryphon Investors, a San Francisco-based middle market private equity firm. Headquartered in California, it delivers trials internationally, offering multiple therapeutic areas including oncology, CNS, cardiovascular, respiratory and ophthalmology.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing